Monoclonal gammopathies require careful monitoring from "summary" of Hematology Board Review by Francis P. Worden, MD,Rami N. Khoriaty, MD,Kathleen A. Cooney, MD,Michael W. Deininger, MD, PhD

Patients with monoclonal gammopathies, such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS), must be closely monitored over time. This is because these conditions can progress and cause serious complications if not managed appropriately. Regular monitoring allows healthcare providers to track the progression of the disease and adjust treatment plans accordingly. One of the key reasons for careful monitoring is to assess the level of monoclonal protein in the blood. This protein, also known as M protein, is produced by abnormal plasma cells and can be detected through blood tests. Monitoring the level of M protein is crucial for determining the response to treatment and detecting any relapse or disease progression. In addition to monitoring M protein levels, healthcare providers also need to keep a close eye on other markers of disease activity, such as beta-2 microglobulin, lactate dehydrogenase, and albumin...

Continue reading the Microbook on the Oter App. You can also listen to the highlights by choosing micro or macro audio option on the app. Download now to keep learning!

Hematology Board Review

Francis P. Worden, MD

Open in app

Now you can listen to your microbooks on-the-go. Download the Oter App on your mobile device and continue making progress towards your goals, no matter where you are.